Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Bayer

Status and phase: Completed; Phase 2

Conditions: Atrial Fibrillation

Treatments: Drug: Capadenoson (BAY68-4986)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00568945

12679

2007-003619-30 (EudraCT Number)

Details and patient eligibility

About

This trial has the primary goal to show that BAY68-4986 can lower the ventricular rate in patients with the indication persistent atrial fibrillation.

Enrollment: 28 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and/or female (without childbearing potential) white patients
• History of persistent or permanent atrial fibrillation
• 18 to 75 years of age

Exclusion criteria

• Patients with high-risk cardiovascular diseases
• Stroke or myocardial infarction
• Relevant pathological changes in the ECG or echocardiography
• Medication affecting ventricular response in Afib

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Drug: Capadenoson (BAY68-4986)